Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 86

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Hereditary neuropathic amyloidosis

Not recruiting

Study on NTLA-2001 for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ziclumeran
  • Sponsor:Intellia Therapeutics Inc.

Multiple sclerosis

Not recruiting

Study on Clemastine and Fampridine for Patients with Multiple Sclerosis and Internuclear Ophthalmoparesis

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Clemastine
  • Sponsor:Amsterdam UMC Stichting

Glioblastoma

Not recruiting

Study on Durvalumab and Radiation Therapy for Patients with Recurrent Glioblastoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Oncopole Claudius Regaud

Subarachnoid haemorrhage+2

Not recruiting

Study on Milrinone Infusion for Treating Vasospasm in Patients with Aneurysmal Subarachnoid Hemorrhage

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Milrinone
  • Sponsor:Centre Hospitalier Universitaire D'Angers

Neurodegenerative disorder

Not recruiting

Study of Latozinemab for Patients with Neurodegenerative Diseases Who Previously Participated in a Latozinemab Study

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Latozinemab
  • Sponsor:Alector LLC

Cardiac failure+1

Not recruiting

Study on the Effects of Ferric Derisomaltose on Cognitive Function in Heart Failure Patients with Iron Deficiency

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ferric Derisomaltose
  • Sponsor:Universitaetsmedizin Goettingen

Cerebrovascular accident

Not recruiting

Study on Deferiprone for Preventing Secondary Degeneration in Stroke Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Deferiprone
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Neuroblastoma+1

Not recruiting

Study of Palbociclib with Drug Combinations for Children and Young Adults with Recurrent or Refractory Neuroblastoma and Ewing Sarcoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years
  • Substances:Palbociclib
  • Sponsor:Pfizer Inc.

Parkinson's disease

Not recruiting

Study of Radotinib safety and effectiveness compared to placebo in people with Parkinson's disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Radotinib Dihydrochloride
  • Sponsor:Il-Yang Pharm Co. Ltd.

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Fenebrutinib and Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Partial seizures

Not recruiting

Study on the Safety and Effectiveness of Azetukalner for Adults with Focal Epilepsy Taking 1 to 3 Anti-Seizure Medications

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Demyelination

Not recruiting

Study on the Effectiveness and Safety of Rozanolixizumab for Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOG-AD)

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rozanolixizumab
  • Sponsor:UCB Biopharma

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.